未登录 分享 收藏
Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance 日本患者中恩曲替尼治疗ROS1基因融合阳性、不可切除的局部晚期/复发性非小细胞肺癌的实世界安全性与有效性：上市后监测 Seto, Takashi; Nakane, Sayuri; Ji, Lyu; Ueda, Yuya; Sugano, Hiroshi; Takei, Nobuki; Kobayashi, Mizuki; Murayama, Ayako; Yamamoto, Noboru 分享 收藏
RELAY: final overall survival with erlotinib plus ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC) Nakagawa, K.; Garon, E. B.; Nishio, M.; Seto, T.; Nishio, K.; Kasahara, K.; Nishino, K.; Satouchi, M.; Yoh, K.; Hayashi, H.; Enatsu, S.; Frimodt-Moller, B.; Matsui, T.; Varughese, S. C.; Visseren-Grul, C.; Reck, M. 分享 收藏
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer Nogami, Naoyuki; Tokito, Takaaki; Zenke, Yoshitaka; Satouchi, Miyako; Seto, Takashi; Saka, Hideo; Ohtani, Junko; Han, Shirong; Noguchi, Kazuo; Nishio, Makoto 分享 收藏
分享 收藏
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR plus non-small-cell lung cancer Nishio, Makoto; Atagi, Shinji; Goto, Koichi; Hosomi, Yukio; Seto, Takashi; Hida, Toyoaki; Nakagawa, Kazuhiko; Yoshioka, Hiroshige; Nogami, Naoyuki; Maemondo, Makoto; Nagase, Seisuke; Okamoto, Isamu; Yamamoto, Noboru; Igawa, Yuriko; Tajima, Kosei; Fukuoka, Masahiro; Yamamoto, Nobuyuki; Nishio, Kazuto 分享 收藏
分享 收藏
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors Nagasaka, Misako; Ohe, Yuichiro; Zhou, Caicun; Choi, Chang-min; Yang, Nong; Liu, Geoffrey; Felip, Enriqueta; Perol, Maurice; Besse, Benjamin; Nieva, Jorge; Raez, Luis; Pennell, Nathan A.; Dimou, Anastasios; de Marinis, Filippo; Ciardiello, Fortunato; Seto, Takashi; Hu, Zheyi; Pan, Max; Wang, Weiqing; Li, Shuanglian; Ou, Sai-Hong, I 分享 收藏
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma Katsuya, Yuki; Kitano, Shigehisa; Yamashita, Makiko; Ouchi, Mayu; Yagishita, Shigehiro; Hamada, Akinobu; Nakamura, Hiromi; Hosoda, Fumie; Shibata, Tatsuhiro; Motoi, Noriko; Nakayama, Takayuki; Seto, Takashi; Umemura, Shigeki; Hosomi, Yukio; Satouchi, Miyako; Nishio, Makoto; Kozuki, Toshiyuki; Hida, Toyoaki; Ohe, Yuichiro; Horinouchi, Hidehito 分享 收藏
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC Wu, Yi-Long; Lu, Shun; Yang, James Chih-Hsin; Zhou, Jianying; Seto, Takashi; Ahn, Myung-Ju; Su, Wu-Chou; Yamamoto, Noboru; Kim, Dong-Wan; Paolini, Jolanda; Usari, Tiziana; Iadeluca, Laura; Wilner, Keith D.; Goto, Koichi 分享 收藏
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: Co-MET study Toyozawa, Ryo; Nosaki, Kaname; Shimokawa, Mototugu; Horinouchi, Hidehito; Morise, Masahiro; Ohashi, Kadoaki; Murakami, Haruyasu; Satouchi, Miyako; Sakakibara, Jun; Yano, Seiji; Matsumoto, Shingo; Goto, Koichi; Seto, Takashi; Yoh, Kiyotaka 分享 收藏
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC Entrectinib治疗ROS1融合阳性NSCLC的长期疗效和安全性 Drilon, Alexander; Chiu, Chao-Hua; Fan, Yun; Cho, Byoung Chul; Lu, Shun; Ahn, Myung-Ju; Krebs, Matthew G.; Liu, Stephen, V; John, Thomas; Otterson, Gregory A.; Tan, Daniel S. W.; Patil, Tejas; Dziadziuszko, Rafal; Massarelli, Erminia; Seto, Takashi; Doebele, Robert C.; Pitcher, Bethany; Kurtsikidze, Nino; Heinzmann, Sebastian; Siena, Salvatore 分享 收藏
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L) Haratake, Naoki; Hayashi, Hidetoshi; Shimokawa, Mototsugu; Nakano, Yusuke; Azuma, Koichi; Oki, Masahide; Ota, Keiichi; Yoshioka, Hiroshige; Sakamoto, Tomohiro; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko; Seto, Takashi 分享 收藏
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) 阿特珠单抗联合贝伐单抗治疗PD-L1高表达非鳞状非小细胞肺癌的II期研究 (@ Be研究) Seto, Takashi; Nosaki, Kaname; Shimokawa, Mototsugu; Toyozawa, Ryo; Sugawara, Shunichi; Hayashi, Hidetoshi; Murakami, Haruyasu; Kato, Terufumi; Niho, Seiji; Saka, Hideo; Oki, Masahide; Yoshioka, Hiroshige; Okamoto, Isamu; Daga, Haruko; Azuma, Koichi; Tanaka, Hiroshi; Nishino, Kazumi; Tohnai, Rie; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko 分享 收藏
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors Afatinib联合xtuzumab (BI 836845) 在EGFR酪氨酸激酶抑制剂治疗进展后EGFR突变阳性NSCLC患者中的1b期开放标签试验 Park, Keunchil; Tan, Daniel Shao Weng; Su, Wu-Chou; Cho, Byoung Chul; Kim, Sang-We; Lee, Ki Hyeong; Wang, Chin-Chou; Seto, Takashi; Huang, Dennis Chin-Lun; Jung, Helen Hayoun; Hsu, Ming-Chi; Bogenrieder, Thomas; Lin, Chia-Chi 分享 收藏
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue Takamori, Shinkichi; Matsubara, Taichi; Haratake, Naoki; Toyokawa, Gouji; Fujishita, Takatoshi; Toyozawa, Ryo; Ito, Kensaku; Yamaguchi, Masafumi; Taguchi, Kenichi; Okamoto, Tatsuro; Seto, Takashi 分享 收藏
Phase 2 trial of atezolizumab with bevacizumab for patients with PD-L1 high non-Sq NSCLC (WJOG10718L/At Be Study) Nakamura, Atsushi; Seto, Takashi; Hayashi, Hidetoshi; Murakami, Haruyasu; Niho, Seiji; Kato, Terufumi; Saka, Hideo; Yoshioka, Hiroshige; Okamoto, Isamu; Azuma, Koichi; Daga, Haruko; Miura, Satoru; Nishino, Kazumi; Tohnai, Rie; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko 分享 收藏
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours Paz-Ares, L.; Barlesi, F.; Siena, S.; Ahn, M-J; Drilon, A.; Conley, A.; Rolfo, C.; Wolf, J.; Seto, T.; Doebele, R.; Kapre, A.; Chen, D.; McCallum, S.; Osborne, S.; Demetri, G. 分享 收藏
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset Ramucirumab联合厄洛替尼与安慰剂联合厄洛替尼治疗未治疗的转移性EGFR突变NSCLC患者: 中继日本子集 Nishio, Kazuto; Seto, Takashi; Nishio, Makoto; Reck, Martin; Garon, Edward B.; Sakai, Kazuko; Goto, Koichi; Kato, Terufumi; Nakanishi, Yoichi; Takahashi, Toshiaki; Yamamoto, Nobuyuki; Kiura, Katsuyuki; Ohe, Yuichiro; Tamura, Tomohide; Visseren-Grul, Carla; Frimodt-Moller, Bente; Hozak, Rebecca R. 分享 收藏
Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer 尼妥珠单抗联合同步放化疗治疗局部晚期非小细胞肺癌的2期临床研究 Yamamoto, Nobuyuki; Harada, Hideyuki; Okamoto, Isamu; Masuda, Noriyuki; Hayakawa, Kazushige; Satouchi, Miyako; Soejima, Toshinori; Nishio, Makoto; Kozuka, Takuyo; Takeda, Koji; Tanaka, Masahiro; Seto, Takashi; Sasaki, Tomonari; Tsubouchi, Hiroshi; Kakurai, Yasuyuki; Nishimura, Yasumasa; Nakagawa, Kazuhiko 分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
